BGM
Get informed when a big investor buys or sells
+ FollowOvervalued by 116.9% based on the discounted cash flow analysis.
| Market cap | $53.15 Million |
|---|---|
| Enterprise Value | $46.31 Million |
| Dividend Yield | $- (-) |
| Earnings per Share | $-5.4 |
| Beta | 1.87 |
| Outstanding Shares | 6,187,063 |
| P/E Ratio | -2.22 |
|---|---|
| PEG | -1.54 |
| Price to Sales | 0.72 |
| Price to Book Ratio | 0.13 |
| Enterprise Value to Revenue | 0.62 |
| Enterprise Value to EBIT | -2.72 |
| Enterprise Value to Net Income | -3 |
| Total Debt to Enterprise | 0.1 |
| Debt to Equity | 0.01 |
No data
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.00000% |
|---|---|
| Total Calls | - |
| Total Puts | - |
Holdings and activity of institutional investors.
| Ownership % | 0.20%▲ 0.09% |
|---|---|
| Total Invested | $139,269▲ 119.72% |
| Investors Holding | 12▼ 2.00% |
No data
Qilian International Holding Group Limited, headquartered in Gansu, China, is a pharmaceutical and chemical products manufacturer in China. It focuses on the development, manufacture, marketing and sale of licorice products, oxytetracycl...